Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Arcoma AB's Enterprise Value is kr91.2 Mil.
Arcoma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr15.6 Mil. Therefore, Arcoma AB's EV-to-FCF for today is 5.83.
The historical rank and industry rank for Arcoma AB's EV-to-FCF or its related term are showing as below:
OSTO:ARCOMA'
s EV-to-FCF Range Over the Past 10 Years
Min: -5193.7 Med: -5.19 Max: 219.76
Current: 5.85
During the past 13 years, the highest EV-to-FCF of Arcoma AB was 219.76. The lowest was -5193.70. And the median was -5.19.
OSTO:ARCOMA's EV-to-FCF is ranked better than 90.87% of 416
companies
in the Medical Devices & Instruments industry
Industry Median: 23.305
vs OSTO:ARCOMA: 5.85
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Arcoma AB's share price for today is kr8.04.
Arcoma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.270.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Arcoma AB EV-to-FCF Related Terms
Arcoma AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Arcoma AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ARCOMA vs ABT, SYK, MDT: EV-to-FCF Comparison
For the Medical Devices subindustry, Arcoma AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcoma AB EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Arcoma AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Arcoma AB's EV-to-FCF falls into.
Arcoma AB's current Enterprise Value is kr91.2 Mil.
Arcoma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr15.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcoma AB (OSTO:ARCOMA) has a EV-to-FCF of 5.83 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Arcoma AB and its competitors. According to the industry distribution chart, Arcoma AB ranks #38 out of 416 companies in the Medical Devices & Instruments industry, placing it in the top 9.1%.
Is Arcoma AB's EV-to-FCF too high?
Arcoma AB's current EV-to-FCF is 5.83. The Medical Devices & Instruments industry median EV-to-FCF is 23.31. Arcoma AB's value of 5.83 is 75% below this industry median. Based on the distribution chart, Arcoma AB ranks #38 out of 416 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Arcoma AB has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arcoma AB's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Arcoma AB ranks #38 out of 416 companies for EV-to-FCF. This places Arcoma AB in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 23.31. Arcoma AB's value of 5.83 is 75% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.31, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcoma AB's current EV-to-FCF of 5.83 is 75% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Arcoma AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcoma AB's current EV-to-FCF is 5.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcoma AB stock overvalued right now?
Based on GuruFocus' analysis, Arcoma AB (OSTO:ARCOMA) is currently considered Fairly Valued. The stock's GF Value™ is kr7.87, compared to a current price of kr8.04 — trading 2.2% above its estimated fair value. The current EV-to-FCF is 5.83 and 75% below the Medical Devices & Instruments industry median of 23.31. Arcoma AB's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Arcoma AB (OSTO:ARCOMA), the current EV-to-FCF is 5.83 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcoma AB (OSTO:ARCOMA) Overvalued in 2026?
Based on GuruFocus' analysis, Arcoma AB stock appears to be overvalued.
The current stock price of kr8.04 is trading 2.2% above its estimated GF Value™ of kr7.87.
GuruFocus considers Arcoma AB to be Fairly Valued.
Key valuation signals for OSTO:ARCOMA:
EV-to-FCF: 5.83
GF Value™: kr7.87 vs. price of kr8.04 (2.2% above fair value)
Industry Position: 75% below the Medical Devices & Instruments median (#38 of 416)
No single metric tells the full story. See the OSTO:ARCOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcoma AB provides digital radiography systems in Sweden. It offers products including wireless flat panel detectors, positioning devices, and precision dr systems.
75GF Score
Get the complete analysis for OSTO:ARCOMA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ARCOMA has been successfully added to your 
